The Annual General Meeting of BioGaia AB (publ) on 10 May 2016 voted to approve
the following resolutions:
· adoption of the annual report
· discharge from liability for the Board members and the Managing Director
· a dividend of SEK 5.00 per share
· re-election of Board members Jan Annwall, Ewa Björling, David Dangoor,
Stefan Elving, Inger Holmström, Anthon Jahreskog, Brit Stakston and Paula Zeilon
· re-election of David Dangoor as Board Chairman
· re-election of the registered Accounting firm Deloitte AB
· Board member compensation in an amount of SEK 300,000 to the Chairman and
SEK 150,000 to each of the other Board members not employed by the company
· auditors’ fee shall be paid according to approved account
· regarding principles for remuneration and other terms of employment for
senior executives in accordance with the Board’s proposal
· regarding the Nominating Committee in accordance with the Nominating
Committee’s proposal
Latest press releases from BioGaia
2016-05-10 BioGaia AB Interim management statement 1 January – 31 March 2016
2016-05-02 Yet another meta-analysis confirms the effectiveness of BioGaia’s
probiotic in infantile colic
2016-04-27 BioGaia guarantees rights issue in IBT
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of NASDAQ Stockholm main market. www.biogaia.com
(http://www.biogaia.com)
